Oral Clinical Trials in Chicago, Illinois
27 recruitingChicago, Illinois
Showing 1–20 of 27 trials
Recruiting
Phase 2
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled40 locationsNCT07195734
Recruiting
Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+2 more
National Cancer Institute (NCI)188 enrolled177 locationsNCT04671667
Recruiting
Phase 2Phase 3
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7+6 more
National Cancer Institute (NCI)613 enrolled341 locationsNCT01810913
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled176 locationsNCT06589804
Recruiting
Phase 2
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+38 more
NRG Oncology98 enrolled149 locationsNCT06532279
Recruiting
Phase 2Phase 3
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Oral Squamous Cell Carcinoma
Privo Technologies40 enrolled4 locationsNCT05893888
Recruiting
Phase 1
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+23 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 1
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Advanced Urothelial CarcinomaOral Drug AdministrationOpen Label
Flare Therapeutics Inc.120 enrolled12 locationsNCT05929235
Recruiting
Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
Recurrent Mucosal MelanomaMucosal MelanomaAnal Melanoma+14 more
National Cancer Institute (NCI)101 enrolled147 locationsNCT05111574
Recruiting
Phase 2Phase 3
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Tongue Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaStage I Lip and Oral Cavity Cancer AJCC v8+9 more
NRG Oncology686 enrolled106 locationsNCT04333537
Recruiting
Phase 3
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Mesial Temporal Lobe Epilepsy
Neurona Therapeutics88 enrolled33 locationsNCT05135091
Recruiting
Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Head and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8+13 more
ECOG-ACRIN Cancer Research Group189 enrolled640 locationsNCT02734537
Recruiting
Not Applicable
Testing the Effectiveness and Implementation of a Meditation App for Youth in the Legal System
Behavioral Health
University of Illinois at Chicago300 enrolled1 locationNCT06997120
Recruiting
Not Applicable
Impact of Hospital to Home: Optimizing Preterm Infant Environment for Surgical Neonates and Their Parents (H-HOPE)
Oral Feeding OutcomesNeurodevelopment Outcome
Ann & Robert H Lurie Children's Hospital of Chicago40 enrolled1 locationNCT07372898
Recruiting
Not Applicable
LH Canine Therapy Study
Emotion RegulationSelf EsteemBehavioral Disorder
University of Chicago48 enrolled2 locationsNCT05840198
Recruiting
Not Applicable
Hip Arthroscopy Postoperative Opioid Demands
PainOpioid UseFemoral Acetabular Impingement+1 more
Rush University Medical Center170 enrolled1 locationNCT04094701
Recruiting
Not Applicable
Trial to Compare the Effects of Myo Munchee Therapy and Oral Motor Therapy (OMT) in Pediatric Patients to Treat Maxillary Deficiency and Orofacial Myofunctional Dysfunction (OMD).
Orofacial Myofunctional DisordersMyo MuncheeOral Motor Therapy+1 more
Myo Munchee (Operations) Pty Ltd48 enrolled2 locationsNCT07088055
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Amyotrophic Lateral SclerosisCorticobasal Degeneration (CBD)Progressive Supranuclear Palsy (PSP)+11 more
Mayo Clinic2,100 enrolled27 locationsNCT04363684
Recruiting
Phase 2
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Oral Mucositis
EpicentRx, Inc.216 enrolled14 locationsNCT05966194